PhotoOpTx

PhotoOpTx is a medical device company leading the way in research and development of photobiomodulation treatment protocols for patients with unmet needs and disease states.

Diabetes is the leading cause of new blindness in the United States, with diabetic macular edema affecting up to 10% of those diagnosed. Vision loss has a significant impact on the lives of those who experience it as well as on their families, their friends, and society. The complete loss or the deterioration of existing eyesight can feel frightening and overwhelming, leaving those affected to wonder about their ability to maintain their independence, pay for needed medical care, retain employment, and provide for themselves and their families.

What is diabetic macular edema (DME)? DME is a complication of diabetes caused by fluid accumulation in the macula that can affect the fovea. The macula is the central portion in the retina which is in the back of the eye and where vision is the sharpest. Vision loss from DME can progress over a period of months and make it impossible to focus clearly.

Through innovative research, PhotoOpTx has created Retilux ®, a safe, non-pharmacological and effective laser therapy device made to enhance the overall quality of life by preventing, or mitigating visual disorders experienced over the entire human lifespan. Our goal is to change how DME is treated and improve how we see in the future.

Company’s Keywords:

ophthalmology, photobiomodulation, laser therapy, diabetic macular edema, vision